Home›Screener›JANX›Profile
D
38/100

Janux Therapeutics

JANXImmuno-Oncology
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

Janux Therapeutics (JANX) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[2], including 2 Phase 1[1].

No Form 4 insider filings for JANX were recorded at the SEC in the past 30 days[3].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. SEC EDGAR · 0001817713 (2026-04-11) ↗
🔬
Clinical Trials
2
NCT05519449Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05783622Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma, Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple-negative Breast Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
0 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Sector Peers (Immuno-Oncology)
AGENAgenus Inc
C
CLDXCelldex Therapeutics
C
RCUSArcus Biosciences
D
ARQTArcus Biosciences
F
Data Provenance
cik1 verified
clinical trial2 verified
insider buy1 verified
trial count2 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR